Trials / Completed
CompletedNCT00876304
Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia
Phase 1, Investigator And Subject-Blind, Placebo-Controlled, Randomized, Sequential Group, Multiple Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04802540 In Patients With Schizophrenia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Taisho Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to subjects with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-04802540 | Multiple ascending doses for 10 days; planned doses include capsules totaling 5 mg and 20 mg every 12 hours, with additional doses determined based on accumulating data |
| DRUG | Placebo | Placebo capsules every 12 hours for 10 days |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2009-04-06
- Last updated
- 2010-03-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00876304. Inclusion in this directory is not an endorsement.